Latest Articles
-
Buy, Sell, Or Hold Medtronic At $100?
Medtronic (NYSE: MDT) stock declined 12% from $115 levels in the beginning of this year to $101 levels on April 20, compared to a 13% decline for the broader S&P 500. While Medtronic’s stock has performed in line with the broader market...
-
Medtronic Stock To See Over 20% Uptick Post Coronavirus?
Medtronic (NYSE: MDT) stock could see growth of over 20% from the recent lows of around $85 levels, going by trends seen during the 2008 slowdown. It is likely that Medtronic stock could bounce back strongly and potentially outperform the broader...
-
Medtronic’s Revenue To Top $34 Billion In Fiscal 2022?
Medtronic’s (NYSE:MDT) revenue grew at a CAGR of 2.0% from $29.7 billion in fiscal 2016 to $30.6 billion in fiscal 2019, and it is estimated to top $34 billion in 2022, led by its Restorative Therapies Group segment. Cardiac & Vascular...
-
Abbott’s EPS Growth Is 2x Compared To Medtronic’s
Abbott’s (NYSE:ABT) adjusted earnings per share (EPS) grew at a CAGR of 11% from $2.16 in 2015 to $3.26 in 2019. This was almost 2x the CAGR of 5.1% for Medtronic’s (NYSE:MDT) adjusted EPS, which grew from $4.28 in fiscal 2015 to $...
-
Does Medtronic’s Current P/E Ratio Offer Any Opportunity To Investors?
The market currently estimates Medtronic’s (NYSE:MDT) revenue growth to be around 3%, whereas the S&P 500’s expected revenue growth is about 7% in 2020. As we discuss below, Medtronic’s margins have been consistently higher...
-
Medtronic Spending Less On Building, And More On Selling?
Medtronic (NYSE:MDT) spends more money on selling, and less on building. In fact, the company’s selling, general & administrative expenses (SG&A) were 40% of its total expenditure in 2018. This compares with 35% of total expenses o...
-
What’s Driving Medtronic’s Revenue Growth?
Medtronic’s (NYSE:MDT) revenue has grown around 6% over the last three years. This can be attributed to steady growth in its Restorative Therapies Group, Cardiac & Vascular Group, and Diabetes Group, partly offset by a decline in the M...
-
Why Did Medtronic’s Stock Grow Around 20% Over The Last 2 Years?
Medtronic’s (NYSE:MDT) share price has grown around 20% over the last two years. This can be attributed to steady growth in its revenues, margin expansion, price to earnings multiple growth, and lower share count. In this note we discuss t...
-
How Does Medtronic’s Diabetes Care Business Compare To Its Peers?
Medtronic’s (NYSE:MDT) diabetes care business could grow in high-single-digits from $2.4 billion in fiscal 2019 to $2.8 billion in fiscal 2021, according to Trefis estimates. This growth will likely be led by expansion of MiniMed product l...
-
How Did Medtronic Fare In Q4, And What Can We Expect From Fiscal 2020?
Medtronic (NYSE:MDT) recently reported its Q4 fiscal 2019 results, which were above our estimates, led by the Restorative Therapies Group. This note details the company’s Q4 performance, and Trefis’ forecasts for the full fiscal 2020. You can vi...
-
How Is Medtronic Likely To Have Fared In Q4 Fiscal 2019?
Medtronic (NYSE:MDT) is expected to publish its Q4 fiscal 2019 results on May 23. This note details Trefis’ forecasts for Medtronic, as well as some of the key trends we will be watching when the company reports earnings. You can view our intera...
-
How Much Can Medtronic’s Earnings Grow In Fiscal 2019?
Medtronic (NYSE:MDT) recently reported its Q3 fiscal 2019 results, which were above our estimates. The company saw steady growth in most of its business segments. However, Cardiac & Vascular Group, which includes rhythm management devices, a...
-
What Factors Will Drive Medtronic’s Earnings Growth In Q3 FY19?
Medtronic (NYSE:MDT) is set to report its Q3 fiscal 2019 earnings on February 19, and we expect the company to post mid-single-digit top line and bottom line growth. The company will likely see steady growth across its segments. Coronary & S...
-
Diabetes Will Lead Medtronic’s Near Term Earnings Growth
Medtronic (NYSE:MDT) recently posted its Q2 FY19 numbers, which were better than street estimates, led by a steady growth across its segments. The company also revised its revenue guidance upward, and expects strong growth in the Diabetes segmen...
-
A Look At Medtronic’s Revenue Sources And Outlook
Medtronic (NYSE:MDT) generates its revenues from sales of Surgical & Patient Monitoring products, Neurological products, Cardiac Rhythm Management products, Cardiovascular products, and Diabetes products. Surgical & Patient Monitoring is...
